Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131640 | 1.00 | BTK (0.36) | BTKTSHRKMT2AGAA | |
| SCHEMBL2712968 | 0.98 | TSHR (0.37) | BTKTSHRKMT2AGAA | |
| SCHEMBL9744380 | 0.98 | TSHR (0.37) | BTKTSHRKMT2AGAA | |
| SCHEMBL647264 | 0.98 | TSHR (0.37) | BTKTSHRKMT2AGAA | |
| SCHEMBL9744375 | 0.98 | TSHR (0.37) | BTKTSHRKMT2AGAA | |
| SCHEMBL4328796 | 0.98 | TSHR (0.37) | BTKTSHRKMT2AGAA | |
| SCHEMBL3672475 | 0.98 | BTK (0.36) | BTKTSHRKMT2A | |
| Hydrochloric Acid SCHEMBL30546580 | 0.97 | TSHR (0.36) | BTKTSHRKMT2AGAA | |
| SCHEMBL2350718 | 0.93 | KMT2A (0.34) | BTKKMT2AGAA | |
| SCHEMBL2350728 | 0.93 | KMT2A (0.34) | BTKKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| EP-2118080-B1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2644618-B1 | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators | OCERA THERAPEUTICS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2644618-A1 | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators | Tranzyme Pharma, Inc. (CA) | 2013-10-02 | — | — | EP | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| EP-1677782-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-07-12 | — | — | EP | disclosed |
| US-20050130959-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-06-16 | — | — | US | disclosed |
| WO-2005039496-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-05-06 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | BTK 2847/4885TSHR 3750/4885KMT2A 4282/4885 |
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | GHSR, GHRHR, GIPR | BTK 4036/4885TSHR 64/4885KMT2A 1898/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | BTK 4126/4885TSHR 72/4885KMT2A 1400/4885 |
| US-20050130959-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | BTK 2847/4885TSHR 3750/4885KMT2A 4282/4885 |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | AAK1, NCK1, DAPK2 | BTK 510/4885TSHR 4742/4885KMT2A 2190/4885 |
| US-10035777-B2 | Heterocyclic kinase inhibitors | AAK1, NCK1, DAPK2 | BTK 510/4885TSHR 4742/4885KMT2A 2190/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | BTK 4036/4885TSHR 64/4885KMT2A 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.